



BC PharmaCare Newsletter

July 8, 2014 Edition 14-004

Published by the Medical Beneficiary and Pharmaceutical Services Division to provide information for British Columbia’s health care providers

QuickLinks

Medication Review Services—Text Correction.....	1
New Adjustment Code for Pharmacy Services Claims	1
Benefits	2
Changes to the Reference Drug Price for ACE Inhibitors—Effective August 8, 2014.....	2

MEDICATION REVIEW SERVICES—TEXT CORRECTION

An error of omission in the text of the newly revised Medication Review Services policy has been identified. Please note that the final bullet in the PharmaCare Policy Manual, [Section 8.9](#), page 16, has been amended with the addition shown in red below:

- The maximum PharmaCare reimburses for a combination of medication review services, clinical services, or administration of vaccines **for the same patient**, on the same day, from the same pharmacy, is \$70.

NEW ADJUSTMENT CODE FOR PHARMACY SERVICES CLAIMS

A new adjustment code, effective April 1, 2014, was added to PharmaNet in order to accommodate the new services claims limit of \$70 per patient per pharmacy per day limit.

The code **SC – Service Claims Net Adjustment** will now appear on Remittances Advices whenever a payment adjustment is made as a result of the services claim limit.

>> For more information on the policy, see the PharmaCare Policy Manual, [Section 8.9](#), Medication Review Services Policy, page 16.

The use of PharmaNet is not intended as a substitute for professional judgment.
Information on PharmaNet is not exhaustive and cannot be relied upon as complete.

The absence of a warning about a drug or drug combination is not an indication that the drug or drug combination is safe, appropriate or effective in any given patient.
Health care professionals should confirm information obtained from PharmaNet, and ensure no additional relevant information exists, before making patient care decisions.

BENEFITS

Changes to the Reference Drug Price for ACE Inhibitors—Effective August 8, 2014

The addition of a new generic version of quinapril will result in a change to the maximum reimbursement for the Angiotensin Converting Enzyme (ACE) Inhibitors Reference Drug Program (RDP) Category.

Effective **August 8, 2014**:

- All listed products of captopril, cilazapril, quinapril, ramipril and trandolapril will be reference products within the category. As such, they will continue to be fully covered according to the rules of the LCA Program and subject to the Maximum Pricing Policy.
- Non-reference products within the category will be partially covered up to the new reference price for the category of \$19.941/30 days, which represents a maximum of 40mg of generic quinapril daily.

Note: If the daily cost of a non-reference product is lower than the reference price for the category, the product is fully covered according to the rules of the LCA Program, subject to the Maximum Pricing Policy.

>>For full information on the RDP, visit www.health.gov.bc.ca/pharmacare/lca/lcabooklets.html.

Regular Benefits

The following product is now an eligible PharmaCare benefit for Fair PharmaCare and Plans B, C, and F.

DIN	DRUG NAME	PLAN G	PLAN P
02373955	colesevelam (Lodalis) 625 mg tablet	N	N

Limited Coverage Drug Program Benefits

The following products are eligible benefits under the Limited Coverage Program—by Special Authority only—for Fair PharmaCare and Plans B, C, and F. For the Special Authority criteria, please visit the [Special Authority Information](http://www.health.gov.bc.ca/pharmacare) page on the PharmaCare website at www.health.gov.bc.ca/pharmacare.

DIN	DRUG NAME	PLAN G	PLAN P
02404508	dimethyl fumarate (Tecfidera™) 120 mg delayed-release capsule	N	N
02420201	dimethyl fumarate (Tecfidera™) 240 mg delayed-release capsule	N	N

Non-Benefits

The following products have been reviewed and will not be added as benefits under PharmaCare.

DIN	DRUG NAME
02400987	ingenol mebutate (Picato®) 0.015% topical gel
02400995	ingenol mebutate (Picato®) 0.05% topical gel
02391678	zolpidem (Sublinox) 5 mg sublingual orally disintegrating tablet
02370433	zolpidem (Sublinox) 10 mg sublingual orally disintegrating tablet